“CBD showed no reduction in the severity of RLS manifestations in patients with PD and RBD,” authors concluded.
Topic: CBD
Authors concluded, “The findings reported here emphasize the continued need for clear and consistent regulation from federal and state agencies to ensure label accuracy of CBD products.”
Researchers reported, “Topical CBD treatment demonstrated significant improvements in … arthritis-related pain and disability without adverse events.”
Compared to the placebo group, subjects receiving CBD extracts experienced significant improvements in their ASD symptoms.
Judges opined that the process used to manufacture the end product was irrelevant as long as it was initially sourced from either hemp or hemp-derived CBD.
Authors concluded: “[A]cute, oral CBD treatment at doses up to 1500 mg does not induce feelings of intoxication and is unlikely to impair cognitive function or driving performance.”
Authors concluded: “Both malignant cancer and chronic dermatitis [were] completely resolved within four weeks of twice-daily treatment.”
“Our results indicated a trend of favorable response in the treatment with CBD, which has emerged as a therapeutic option for psoriasis,” researchers concluded.